world-biomarkers-pharma-biotech-2017-tracks

27 / 28

Notes:
Volume10, Issue 12 (Suppl) J Proteomics Bioinform, an open access journal
ISSN: 0974-276X
Page 55
conferenceseries.com
World Biomarkers & Pharma Biotech 2017
December 07-09, 2017
December 07-09, 2017 | Madrid, Spain
&
20th International Conference on
PHARMACEUTICAL BIOTECHNOLOGY
9th WORLD BIOMARKERS CONGRESS
JOINT EVENT ON
Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet
digital PCR
Sayda Omer Ebnaof
University of Khartoum, Sudan
Background: Breast cancer circulating biomarkers include carcinoembryonic antigen and carbohydrate antigen 15–3, which are
used for patient follow-up. Since sensitivity and specificity are low, novel and more useful biomarkers are needed. The presence of
stable circulating microRNAs (miRNAs) in serum or plasma suggested a promising role for these tiny RNAs as cancer biomarkers. To
acquire an absolute concentration of circulating miRNAs and reduce the impact of preanalytical and analytical variables, we used the
droplet digital PCR (ddPCR) technique.
Results: We investigated a panel of five miRNAs in the sera of two independent cohorts of breast cancer patients and disease-free
controls. The study showed that miR-148b-3p and miR-652-3p levels were significantly lower in the serum of breast cancer patients
than that in controls in both cohorts. For these two miRNAs, the stratification of breast cancer patients versus controls was confirmed
by receiver operating characteristic curve analyses. In addition, we showed that higher levels of serum miR-10b-5p were associated
with clinicobiological markers of poor prognosis.
Conclusions: The study revealed the usefulness of the ddPCR approach for the quantification of circulating miRNAs. The use of
the ddPCR quantitative approach revealed very good agreement between two independent cohorts in terms of comparable absolute
miRNA concentrations and consistent trends of dysregulation in breast cancer patients versus controls. Overall, this study supports
the use of the quantitative ddPCR approach for monitoring the absolute levels of diagnostic and prognostic tumor-specific circulating
miRNAs.
Biography
Sayda Omer Ebnaof has completed her PhD in Molecular Biology from University of Ferrara, Italy in 2016 and MSc in Molecular Medicine from Institute of Endemic
Diseases, University of Khartoum-Sudan. She is a Lecturer of Histopathology and Cytology at University of Khartoum. She has published four papers in reputed
journals.
Sayda Omer Ebnaof, J Proteomics Bioinform 2017, 10:12(Suppl)
DOI: 10.4172/0974-276X-C1-109